APO RESEARCH · REPORT
Rivaroxaban
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Product & engineering
Understand the product.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Selected research
Industry Research
Rivaroxaban Industry Research Report 2026
Market perspective
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
Report Scope
Read the full market overview
This report quantifies the global Rivaroxaban market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rivaroxaban Market by Company
Bayer
J&J
Rivaroxaban Segment by Type
2.5 mg
10 mg
15 mg
20 mg
Rivaroxaban Segment by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Rivaroxaban Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rivaroxaban market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rivaroxaban and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rivaroxaban.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rivaroxaban by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rivaroxaban in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 2.5 mg
- 10 mg
- 15 mg
- 20 mg
Applications
- Acute Coronary Syndrome (ACS)
- Venous Thromboembolism (VTE)
Companies covered
- Bayer
- J&J
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rivaroxaban Market Size (2021-2032)
- 2.2.2 Global Rivaroxaban Sales (2021-2032)
- 2.2.3 Global Rivaroxaban Market Average Price (2021-2032)
- 2.3 Rivaroxaban by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 2.5 mg
- 2.3.3 10 mg
- 2.3.4 15 mg
- 2.3.5 20 mg
- 2.4 Rivaroxaban by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Acute Coronary Syndrome (ACS)
- 2.4.3 Venous Thromboembolism (VTE)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rivaroxaban Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Rivaroxaban Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Rivaroxaban Revenue of Manufacturers (2021-2026)
- 3.4 Global Rivaroxaban Average Price by Manufacturers (2021-2026)
- 3.5 Global Rivaroxaban Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Rivaroxaban, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rivaroxaban, Product Type & Application
- 3.8 Global Manufacturers of Rivaroxaban, Established Date
- 3.9 Global Rivaroxaban Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bayer
- 4.1.1 Bayer Company Information
- 4.1.2 Bayer Business Overview
- 4.1.3 Bayer Rivaroxaban Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bayer Rivaroxaban Product Portfolio
- 4.1.5 Bayer Recent Developments
- 4.2 J&J
- 4.2.1 J&J Company Information
- 4.2.2 J&J Business Overview
- 4.2.3 J&J Rivaroxaban Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 J&J Rivaroxaban Product Portfolio
- 4.2.5 J&J Recent Developments
5 Global Rivaroxaban Market Scenario by Region
- 5.1 Global Rivaroxaban Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Rivaroxaban Sales by Region: 2021-2032
- 5.2.1 Global Rivaroxaban Sales by Region: 2021-2026
- 5.2.2 Global Rivaroxaban Sales by Region: 2027-2032
- 5.3 Global Rivaroxaban Revenue by Region: 2021-2032
- 5.3.1 Global Rivaroxaban Revenue by Region: 2021-2026
- 5.3.2 Global Rivaroxaban Revenue by Region: 2027-2032
- 5.4 North America Rivaroxaban Market Facts & Figures by Country
- 5.4.1 North America Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Rivaroxaban Sales by Country (2021-2032)
- 5.4.3 North America Rivaroxaban Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Rivaroxaban Market Facts & Figures by Country
- 5.5.1 Europe Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Rivaroxaban Sales by Country (2021-2032)
- 5.5.3 Europe Rivaroxaban Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Rivaroxaban Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Rivaroxaban Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Rivaroxaban Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rivaroxaban Market Facts & Figures by Country
- 5.7.1 South America Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Rivaroxaban Sales by Country (2021-2032)
- 5.7.3 South America Rivaroxaban Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Rivaroxaban Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rivaroxaban Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Rivaroxaban Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Rivaroxaban Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Rivaroxaban Sales by Type (2021-2032)
- 6.1.1 Global Rivaroxaban Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Rivaroxaban Sales Market Share by Type (2021-2032)
- 6.2 Global Rivaroxaban Revenue by Type (2021-2032)
- 6.2.1 Global Rivaroxaban Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Rivaroxaban Revenue Market Share by Type (2021-2032)
- 6.3 Global Rivaroxaban Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Rivaroxaban Sales by Application (2021-2032)
- 7.1.1 Global Rivaroxaban Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Rivaroxaban Sales Market Share by Application (2021-2032)
- 7.2 Global Rivaroxaban Revenue by Application (2021-2032)
- 7.2.1 Global Rivaroxaban Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Rivaroxaban Revenue Market Share by Application (2021-2032)
- 7.3 Global Rivaroxaban Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rivaroxaban Value Chain Analysis
- 8.1.1 Rivaroxaban Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rivaroxaban Production Mode & Process
- 8.2 Rivaroxaban Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rivaroxaban Distributors
- 8.2.3 Rivaroxaban Customers
9 Global Rivaroxaban Analyzing Market Dynamics
- 9.1 Rivaroxaban Industry Trends
- 9.2 Rivaroxaban Industry Drivers
- 9.3 Rivaroxaban Industry Opportunities and Challenges
- 9.4 Rivaroxaban Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst